Growth factor transduction pathways: paradigm of anti-neoplastic targeted therapy.

摘要: Molecularly targeted cancer treatment has become an achievable goal thanks to systematic analysis of genome as well development highly selective tumor drugs. In many human cancers, deregulation the RTK/RAS/MAPK pathway is driving force disease. Indeed, cells addicted such signaling, rendering them susceptible drugs that can intercept growth factor signaling cascade at different levels. Discovery mutations or aberrant expression components this in radio- and chemotherapy refractory melanoma acted enormous stimulus for scientist try identify clinically test new therapeutic approaches blocking cascade. These efforts not only resulted identification but also a better understanding molecular basis primary secondary resistance therapies.